Post-Menopausal Estrogen Production, with Special Reference to Patients with Mammary Carcinoma

2015 ◽  
pp. 45-62 ◽  
Author(s):  
J. H. H. Thijssen ◽  
J. Poortman ◽  
F. Schwarz ◽  
F. de Waard
Keyword(s):  
Special Reference ◽  
Mammary Carcinoma ◽  
Estrogen Production ◽  
Post Menopausal

scholarly journals Endometrioma mimicking ovarian malignancy in a post-menopausal woman

2021 ◽  
Vol 10 (8) ◽  
pp. 3226
Author(s):  
Vijay Zutshi ◽  
Shreshtha Gupta ◽  
Charanjeet Ahluwalia ◽  
Monica R.
Keyword(s):  
Normal Serum ◽  
Reproductive Age ◽  
Ca 125 ◽  
Menopausal Woman ◽  
Ovarian Malignancy ◽  
Ovarian Endometriosis ◽  
Post Menopausal Woman ◽  
Estrogen Production ◽  
Malignant Ovarian Tumor ◽  
Post Menopausal

Endometriosis is an estrogen dependant disorder of reproductive-age women. It is uncommon after menopause, however, peripheral estrogen production may account for endometriosis in post-menopausal women. We reported a case of a 68 year old post-menopausal woman with an adnexal mass suspected malignant ovarian tumor on imaging and normal serum CA 125 levels. Total hysterectomy with bilateral salpingo-oophorectomy was done. The final histopathology revealed the diagnosis of ovarian endometriosis. Rarely, ovarian endometrioma can mimic ovarian malignancy in a post-menopausal woman.

scholarly journals Memory Decline in Peri- and Post-menopausal Women: The Potential of Mind–Body Medicine to Improve Cognitive Performance

2014 ◽  
Vol 9 ◽  
pp. IMI.S15682 ◽  
Author(s):  
Jim R. Sliwinski ◽  
Aimee K. Johnson ◽  
Gary R. Elkins
Keyword(s):  
Cognitive Decline ◽  
Cognitive Performance ◽  
Hot Flashes ◽  
Integrative Approach ◽  
Future Research ◽  
Memory Decline ◽  
Estrogen Production ◽  
Menopausal Women ◽  
Mind Body Medicine ◽  
Post Menopausal

Cognitive decline is a frequent complaint during the menopause transition and among post-menopausal women. Changes in memory correspond with diminished estrogen production. Further, many peri- and post-menopausal women report sleep concerns, depression, and hot flashes, and these factors may contribute to cognitive decline. Hormone therapy can increase estrogen but is contraindicated for many women. Mind–body medicine has been shown to have beneficial effects on sleep, mood, and hot flashes, among post-menopausal women. Further, mind–body medicine holds potential in addressing symptoms of cognitive decline post-menopause. This study proposes an initial framework for how mind–body interventions may improve cognitive performance and inform future research seeking to identify the common and specific factors associated with mind–body medicine for addressing memory decline in peri- and post-menopausal women. It is our hope that this article will eventually lead to a more holistic and integrative approach to the treatment of cognitive deficits in peri- and post-menopausal women.

scholarly journals Predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women: quod erat demonstrandum?

2009 ◽  
Vol 22 (2) ◽  
pp. 332-335 ◽  
Author(s):  
Mark A. Rodrigues ◽  
Jonathan K. Foster ◽  
Giuseppe Verdile ◽  
Karen Joesbury ◽  
Richard Prince ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Risk Factor ◽  
Neuronal Damage ◽  
Mixed Data ◽  
Memory Decline ◽  
Estrogen Production ◽  
Age Related ◽  
Menopausal Women ◽  
Post Menopausal

Alzheimer's disease (AD) is the major form of age-related dementia worldwide, accounting for more than two-thirds of all dementia cases. The disease is characterized by a progressive loss of cognitive and intellectual functioning (Gilman, 1997). A number of risk factors for AD have been identified. The prevalence of AD increases with age, diabetes, depression, family history of Parkinson's disease and following head injury or exposure to solvents (Jorm et al., 1991; van Duijn et al., 1991; Ott et al., 1995; Yoshitake et al., 1995; Devanand et al., 1996). Published research further suggests that low education levels are associated with increased prevalence of clinical AD (Gatz et al., 2001; Qiu et al., 2001; Ravaglia et al., 2002). Women also have a higher risk for developing the disease than men, with the risk being markedly increased following menopause (Sherwin, 2002; Sherwin 2003). Additionally, slightly more severe cognitive deficits have been reported in AD in women compared to men (Buckwalter et al., 1993, Henderson and Buckwalter, 1994). These epidemiological trends may be a consequence of reproductive hormonal changes. Specifically, menopause results in a marked diminution in gonadal estrogen production in women (see Sherwin, 2003, for a review). Estrogen plays a pivotal role in the maintenance and function of neuronal circuits in the brain and in resistance to neuronal damage (McEwen, 2001). The neuroprotective properties of estrogen are thought to be mediated at least in part by anti-amyloidogenic, anti-oxidative and ant-inflammatory mechanisms (reviewed in Barron et al., 2006a). However, limited and somewhat mixed data exist regarding the association between endogenous levels of estrogen and cognitive decline (Manly et al., 2000; Schupf et al., 2003). Based on some of our own findings, we here consider the factors that may be useful in predicting memory decline as a risk factor for Alzheimer's disease in older post-menopausal women.

scholarly journals Cardiometabolic risk in pre- and post-menopausal women with special reference to insulin resistance: A cross-sectional study

2020 ◽  
Vol 11 (1) ◽  
pp. 22
Author(s):  
AnuradhaVaman Khadilkar ◽  
Utkarshini Kirtikar ◽  
Neha Kajale ◽  
Vivek Patwardhan ◽  
Vaman Khadilkar
Keyword(s):  
Insulin Resistance ◽  
Special Reference ◽  
Cardiometabolic Risk ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Menopausal Women ◽  
Post Menopausal

Antitumoral Activity of Calusterone in Advanced Mammary Carcinoma.

1976 ◽  
Vol 62 (1) ◽  
pp. 79-84
Author(s):  
Riccardo Rosso ◽  
Fulvio Brema ◽  
Gian Franco Porcile ◽  
Leonardo Santi
Keyword(s):  
Side Effects ◽  
Complete Remission ◽  
Disease Progression ◽  
Mammary Carcinoma ◽  
Objective Response ◽  
Antitumoral Activity ◽  
Post Menopausal

Thirty-one post-menopausal patients with advanced mammary carcinoma were treated with calusterone (7-beta, 17-alpha-dimethyl-testosterone), 200 mg daily per os for at least three months. Twenty-seven patients were evaluable. Eight patients (29%) had an objective response; two patients had a complete remission, maintained for more than eighteen months by repeated three-month courses of therapy. In eight patients (29%), calusterone produced no objective response, without disease progression. The main side effects have been hirsutism, acne and gastro-intestinal distress; no libido modification was observed. Increased BSP retention was observed in one third of patients.

Sign in / Sign up

Export Citation Format

Share Document